CD33 and acute myeloid leukemia: GO received the European Medicines Agency’s (EMA) marketing authorization on 19 April 2018 for the treatment of de novo CD33-positive AML patients aged 15 years and above as frontline therapy in combination with daunorubicin and cytarabine.